Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Retrieved on:
Wednesday, April 21, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Medical specialties, Clinical medicine, Infectious diseases, Hepadnaviridae, Hepatitis B, Hepatitis, HBV, BRII-835 (VIR-2218), BRII-179 (VBI-2601), Brii Biosciences, Vir Biotechnology, VBI Vaccines Inc., BRII-835 (VIR-2218), BRII-179 (VBI-2601), BRII BIOSCIENCES, VIR BIOTECHNOLOGY, VBI VACCINES INC.
This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.\nThis press release features multimedia.
Key Points:
- This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.\nThis press release features multimedia.
- Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).
- Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T cell responses specific to HBV.
- Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.